Nipocalimab demonstrates significant clinical improvement in ...

Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in ...

Nipocalimab demonstrates significant clinical improvement

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study. November ...

Nipocalimab is the first and only investigational therapy granted U.S. ...

... clinical evidence that indicates the drug may have substantial improvement in at least one clinically significant endpoint over available ...

Nipocalimab demonstrates significant clinical improvement in ...

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study. Sharing ...

Investigational Nipocalimab Demonstrates Efficacy and Safety in ...

In a small sample population of adolescents with myasthenia gravis, nipocalimab met its primary end point, showing a significant reduction ...

Nipocalimab demonstrates sustained disease control in adolescents ...

Results show a significant reduction in IgG of approximately 70 percent in adolescents and a clinical benefit that is consistent with the ...

Nipocalimab pivotal Phase 3 trial demonstrates longest sustained ...

Improvement in strength and function of different muscle groups, as measured by QMGd, was significantly greater with nipocalimab plus SOC ...

Autoantibody - Janssen Science

Post-hoc Evaluation of the Clinical Effects of Nipocalimab ... Nipocalimab + SOC demonstrated statistically significant improvement in MG-ADL ...

Nipocalimab Demonstrates Sustained Disease Control in ...

Results show a significant reduction in IgG of approximately 70% in adolescents and a clinical benefit that is consistent with the Vivacity-MG3 ...

Understanding Nipocalimab's Impact on Myasthenia Gravis Using ...

Key Takeaways. Nipocalimab showed significant improvement in MG-ADL scores compared to placebo in the phase 3 Vivacity-MG3 study.

Clinical Use in Sjogren's Disease (SjD) - Janssen Science

Patients treated with nipocalimab 15 mg/kg demonstrated statistically significant (P=0.002) improvement in Clinical European League Against Rheumatism ...

Sustained Control With New mAb for Myasthenia Gravis - Medscape

The investigational monoclonal antibody nipocalimab (Johnson & Johnson) is associated with significant improvement in patients with generalized myasthenia ...

Phase III Vivacity-MG3 Trial Demonstrates Superiority of ...

Additionally, QMG improved significantly over weeks 22 and 24 (P<0.001), and a greater MG-ADL response (≥2-point improvement) with nipocalimab ...

Johnson & Johnson's nipocalimab shows promise in Sjögren's ...

Johnson & Johnson announced findings from the Phase II DAHLIAS dose-ranging study where its monoclonal antibody nipocalimab offered significant improvements in ...

Nipocalimab pivotal Phase 3 trial demonstrates longest sustained ...

MG-ADL response (≥2-point improvement from baseline) was significantly greater in nipocalimab plus SOC compared with placebo plus SOC (P=0.021) ...

AB0250 A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE ...

In a phase 2 study (NCT03772587), nipocalimab reduced pathogenic immunoglobulin G autoantibody levels and demonstrated significant clinical benefits and ...

Safety and Efficacy of Nipocalimab in Patients With Generalized ...

... significantly improve MG-ADL at any individual dose but demonstrated a significant dose response for improved MG-ADL across doses.

'Proof of concept' established for FcRn receptor blocker nipocalimab ...

Patients with Sjögren's disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate significant improvement vs. those who receive ...

J&J's $6.5B Momenta Buy Pays Off With Phase II Sjögren's Disease ...

... nipocalimab, demonstrating significant symptomatic improvement in patients with the chronic autoimmune Sjögren's disease. At 24 weeks ...

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with ...

... clinical improvement. Conclusions. Despite not achieving statistical significance in the primary endpoint, nipocalimab showed consistent ...